A matter of trust: Reengaging communities of color in clinical trials
For Argentino Calvo, a retired firefighter and paramedic from Bluffton, South Carolina, joining a COVID-19 vaccine trial was not just a personal choice but an investment in the health of his community.
Calvo participated in the Novavax vaccine trial at MUSC, which was part of a large-scale study that recruited over 30,000 patients across 119 study sites in the United States and Mexico. SCTR co-principal investigator Patrick Flume, M.D. is leading MUSC’s studies on vaccine candidates, which includes the Novavax vaccine trial.